https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46793 Wed 30 Nov 2022 14:10:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24519 Wed 09 Mar 2022 16:03:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34282 Tue 26 Feb 2019 12:16:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27845 Sat 24 Mar 2018 07:41:17 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:27092 Sat 24 Mar 2018 07:40:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22862 Sat 24 Mar 2018 07:16:01 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46642 p < 0.0001). There was no heterogeneity of the effects of BP lowering (intensive vs. guideline) on functional recovery between standard-dose (OR 0.81, 95% CI 0.59-1.12) and low-dose alteplase (1.06, 0.77-1.47; p = 0.25 for interaction). Similar results were observed for ICH (p = 0.50 for interaction). Conclusions: In thrombolysis-treated patients with predominantly mild-to-moderate severity AIS, intensive BP lowering neither improve functional recovery, either with low-or standard-dose intravenous alteplase, nor beneficially interact with low-dose alteplase in reducing ICH. Trial Registration: The trial is registered with ClinicalTrials.gov (NCT01422616).]]> Mon 28 Nov 2022 16:54:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:40030 Fri 22 Jul 2022 13:07:48 AEST ]]>